Prognostic value of MRD monitoring based on BCR-ABL1 copy numbers in Philadelphia chromosome positive acute lymphoblastic leukemia

References

• Ravandi F, O'Brien SM, Cortes JE, et al. Long-Term Follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015;121(23):4158–4164.
   PubMed Web of Science ®Google Scholar
• Lugo TG, Pendergast AM, Muller AJ, et al. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247(4946):1079–1082.
   PubMed Web of Science ®Google Scholar
• Schrappe M, Camitta B, Pui CH, et al. Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia. 2000;14(12):2193–2194.
   PubMed Web of Science ®Google Scholar
• Hoelzer D. Advances in the management of Ph-positive ALL. Clin Adv Hematol Oncol. 2006;4(11):804–805.
   PubMedGoogle Scholar
• Fielding AK, Rowe JM, Richards SM, et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood. 2009;113(19):4489–4496.
   PubMed Web of Science ®Google Scholar
• Dombret H, Gabert J, Boiron J-M, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia–results of the prospective multicenter LALA-94 trial. Blood. 2002;100(7):2357–2366.
   PubMed Web of Science ®Google Scholar
• Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29(5):532–543.
   PubMed Web of Science ®Google Scholar
• Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children’s oncology group study. J Clin Oncol. 2009;27(31):5175–5181.
   PubMed Web of Science ®Google Scholar
• Biondi A, Schrappe M, De Lorenzo P, et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol. 2012;13(9):936–945.
   PubMed Web of Science ®Google Scholar
• Brissot E, Labopin M, Beckers MM, et al. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Haematologica. 2015;100(3):392–399.
   PubMed Web of Science ®Google Scholar
• Bassan R, Rossi G, Pogliani EM, et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group Protocol 09/00. J Clin Oncol. 2010;28(22):3644–3652.
   PubMed Web of Science ®Google Scholar
• Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115(16):3206–3214.
   PubMed Web of Science ®Google Scholar
• Spinelli O, Peruta B, Tosi M, et al. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica. 2007;92(5):612–618.
   PubMed Web of Science ®Google Scholar
• Bar M, Wood BL, Radich JP, et al. Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia. Leuk Res Treat. 2014;2014:1–9.
   Google Scholar
• Ravandi F, Jorgensen JL, Thomas DA, et al. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013;122(7):1214–1221.
   PubMed Web of Science ®Google Scholar
• Cazzaniga G, De Lorenzo P, Alten J, et al. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies. Haematologica. 2018;103(1):107–115.
   PubMed Web of Science ®Google Scholar
• van Dongen J, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Leukemia. 1999;13(12):1901–1928.
   PubMed Web of Science ®Google Scholar
• Moorman AV, Enshaei A, Schwab C, et al. A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia. Blood. 2014;124(9):1434–1444.
   PubMed Web of Science ®Google Scholar
• Gabert J, Beillard E, van der Velden VHJ, et al. Standardization and quality control studies of “'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – a Europe Against Cancer program”. Leukemia. 2003;17(12):2318–2357.
   PubMed Web of Science ®Google Scholar
• Balasubramanian P, Chendamarai E, Markose P, et al. International reporting scale of BCR-ABL1 fusion transcript in chronic myeloid leukemia: first report from India. Acta Haematol. 2012;127(3):135–142.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, O’Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18(3):547–561.
   PubMed Web of Science ®Google Scholar
• Bajel A, George B, Mathews V, et al. Adult ALL: treatment outcome and prognostic factors in an Indian population using a modified German ALL (GMALL) protocol. Leukemia. 2007;21(10):2230–2233.
   PubMed Web of Science ®Google Scholar
• Jain P, Korula A, Deshpande P, et al. Adult acute lymphoblastic leukemia: limitations of intensification of therapy in a developing country. J Glob Oncol. 2018;4:1–12.
   PubMedGoogle Scholar
• Ceppi F, Duval M, Leclerc J-M, et al. Improvement of the outcome of relapsed or refractory acute lymphoblastic leukemia in children using a risk-based treatment strategy. Plos One. 2016;11(9):e0160310.
   PubMed Web of Science ®Google Scholar
• NCI Dictionary of Cancer Terms [Internet]. National Cancer Institute. 2011. [cited 2020 Aug 18]. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms.
   Google Scholar
• Short NJ, Jabbour E, Sasaki K, et al. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2016;128(4):504–507.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457–481.
   Web of Science ®Google Scholar
• Cox DR. Regression models and life-tables. J R Stat Soc Ser B Methodol. 1972;34(2):187–220.
   Web of Science ®Google Scholar
• Lee S, Kim D-W, Cho B-S, et al. Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia. 2012;26(11):2367–2374.
   PubMed Web of Science ®Google Scholar
• Brüggemann M, Kotrova M. Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation. Hematology Am Soc Hematol Educ Program. 2017;2017(1):13–21.
   PubMedGoogle Scholar
• Bar M, Wood BL, Radich JP, et al. Impact of minimal residual disease, as detected by multiparametric flow cytometry pre and post transplantation, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood. 2012;120(21):592–592.
   PubMed Web of Science ®Google Scholar
• Chalandon Y, Thomas X, Hayette S, Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL), et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015;125(24):3711–3719.
   PubMed Web of Science ®Google Scholar
• Alacacioglu I, Medeni SS, Ozsan GH, et al. Is the BFM regimen feasible for the treatment of adult acute lymphoblastic leukemia? A retrospective analysis of the outcomes of bfm and hyper-CVAD chemotherapy in two centers. Chemotherapy. 2014;60(4):219–223.
   PubMed Web of Science ®Google Scholar
• El-Cheikh J, Dika IE, Massoud R, et al. Hyper-CVAD compared With BFM-like chemotherapy for the treatment of adult acute lymphoblastic leukemia. A retrospective single-center analysis. Clin Lymphoma Myeloma Leuk. 2017;17(3):179–185.
   PubMed Web of Science ®Google Scholar
• Kim D-Y, Joo Y-D, Lim S-N, et al. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Blood. 2015;126(6):746–756.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H, Ravandi F, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015;16(15):1547–1555.
   PubMed Web of Science ®Google Scholar
• Arun AK, Senthamizhselvi A, Mani S, et al. Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients. Int J Lab Hematol. 2017;39(3):235–242.
   PubMed Web of Science ®Google Scholar
• Yanada M, Sugiura I, Takeuchi J, Japan Adult Leukemia Study Group, et al. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy. Br J Haematol. 2008;143(4):503–510.
   PubMed Web of Science ®Google Scholar